| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAPG |
| Uniprot No | P40121 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-348aa |
| 氨基酸序列 | MYTAIPQSGSPFPGSVQDPGLHVWRVEKLKPVPVAQENQGVFFSGDSYLVLHNGPEEVSHLHLWIGQQSSRDEQGACAVLAVHLNTLLGERPVQHREVQGNESDLFMSYFPRGLKYQEGGVESAFHKTSTGAPAAIKKLYQVKGKKNIRATERALNWDSFNTGDCFILDLGQNIFAWCGGKSNILERNKARDLALAIRDSERQGKAQVEIVTDGEEPAEMIQVLGPKPALKEGNPEEDLTADKANAQAAALYKVSDATGQMNLTKVADSSPFALELLISDDCFVLDNGLCGKIYIWKGRKANEKERQAALQVAEGFISRMQYAPNTQVEILPQGRESPIFKQFFKDWK |
| 预测分子量 | 65.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAPG重组蛋白的3篇参考文献及其摘要概括：
1. **《Expression and Purification of Recombinant Human CAPG in Escherichia coli》**
- 作者：Zhang, Y. et al.
- 摘要：该研究成功克隆了人源CAPG基因，并利用大肠杆菌表达系统实现了重组蛋白的高效表达，通过亲和层析纯化获得高纯度CAPG，验证了其结合肌动蛋白的生物学活性。
2. **《CAPG Regulates Cell Motility via Interaction with Actin Filaments》**
- 作者：Lee, S. & Matsudaira, P.
- 摘要：通过体外表达重组CAPG蛋白，研究发现其能够调控肌动蛋白丝的组装和解聚，揭示了CAPG在细胞迁移中的关键作用，为肿瘤转移机制提供了新见解。
3. **《Structural Insights into CAPG-Actin Complex by Cryo-EM》**
- 作者：Smith, R.K. et al.
- 摘要：利用重组CAPG蛋白进行冷冻电镜分析，解析了CAPG与肌动蛋白结合的三维结构，阐明了其通过C端结构域调控肌动蛋白动态的分子机制。
4. **《Recombinant CAPG Enhances Invasive Phenotype in Breast Cancer Cells》**
- 作者：Brown, T.E. et al.
- 摘要：研究通过外源性添加重组CAPG蛋白，证明其通过重塑细胞骨架促进乳腺癌细胞的侵袭能力，提示CAPG可能成为抑制转移的潜在靶点。
(注：以上文献为示例性质，实际引用时需核对具体文献来源及准确性。)
CAPG (Macrophage-capping protein), also known as gelsolin-like actin-capping protein, is a cytoskeleton-associated protein belonging to the gelsolin family. It plays a critical role in regulating actin dynamics by capping the barbed ends of actin filaments, thereby controlling cytoskeletal remodeling, cell motility, and membrane protrusion. CAPG is expressed in various tissues, particularly in macrophages, endothelial cells, and certain cancer cells, where it contributes to processes like phagocytosis, inflammation, and metastatic invasion.
Recombinant CAPG protein is engineered using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. Its production enables detailed study of actin-related mechanisms in vitro, bypassing the complexity of endogenous protein isolation. Researchers utilize recombinant CAPG to investigate its interaction with actin, signaling pathways (e.g., Rho GTPases), and roles in diseases such as cancer metastasis, autoimmune disorders, and vascular pathologies. Structurally, CAPG contains conserved gelsolin-like domains at its N- and C-termini, which mediate actin binding and regulatory functions.
The development of recombinant CAPG has facilitated drug discovery, serving as a target for therapies aimed at modulating cytoskeletal dynamics in pathological conditions. It is also employed as a tool in biochemical assays, antibody production, and structural studies. Recent studies highlight its potential as a biomarker in cancer prognosis due to overexpression in aggressive tumors. Despite progress, challenges remain in understanding isoform-specific functions and context-dependent regulatory mechanisms, underscoring the need for continued research using recombinant protein tools.
×
